About MacroGenics, Inc.
Founded in 2000, MacroGenics is a private, venture-backed biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer and infectious diseases. The company's proprietary Fc engineering technology offers ways of improving antibody function, such as enhancing the antibody's ability to eliminate cancer cells, cells that contribute to autoimmune disorders, or those infected with certain pathogens. The company is developing first-in-class product candidates from its autoimmunity, oncology and infectious disease portfolios. For more information about MacroGenics, please visit http://www.macrogenics.com.
This news release contains forward-looking statements. These statements
are subject to known and unknown risks and uncertainties that may cause
actual future experience and results to differ materially from the
statements made. Factors that might cause such a difference include, among
others, the completion of clinical trials, the FDA and other foreign review
processes and other governmental regulation, Lilly and MacroGenics'
abilities to successfully develop and commercialize drug candidates,
competition from other pharmaceutical companies, the ability to effectively
market products, and other factors described in Lilly's most recent filings
with the Securities and Exchange Commission. Lilly undertakes no duty to
update forward lo
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved